Stock Worth Watching: Sentiment Change Report: Zoetis Inc (NYSE:ZTS)

November 25, 2016 - By Ellis Scott   ·   0 Comments

Stock Worth Watching: Sentiment Change Report: Zoetis Inc (NYSE:ZTS)

Sentiment for Zoetis Inc (NYSE:ZTS)

Zoetis Inc (NYSE:ZTS) institutional sentiment increased to 1.19 in Q2 2016. Its up 0.11, from 1.08 in 2016Q1. The ratio is more positive, as 282 investment managers opened new or increased holdings, while 260 sold and reduced holdings in Zoetis Inc. The investment managers in our partner’s database now possess: 451.82 million shares, down from 457.84 million shares in 2016Q1. Also, the number of investment managers holding Zoetis Inc in their top 10 holdings decreased from 22 to 18 for a decrease of 4. Sold All: 48 Reduced: 212 Increased: 210 New Position: 72.

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company has a market cap of $25.04 billion. The Firm has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish , and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. It has a 36.3 P/E ratio. It operates through two divisions: the United States and International.

About 548,209 shares traded hands. Zoetis Inc (NYSE:ZTS) has risen 3.17% since April 22, 2016 and is uptrending. It has underperformed by 2.24% the S&P500.

Analysts await Zoetis Inc (NYSE:ZTS) to report earnings on February, 21. They expect $0.46 earnings per share, up 6.98% or $0.03 from last year’s $0.43 per share. ZTS’s profit will be $229.72 million for 27.26 P/E if the $0.46 EPS becomes a reality. After $0.52 actual earnings per share reported by Zoetis Inc for the previous quarter, Wall Street now forecasts -11.54% negative EPS growth.

According to Zacks Investment Research, “Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.”

Marlowe Partners Lp holds 28.02% of its portfolio in Zoetis Inc for 731,625 shares. Pershing Square Capital Management L.P. owns 21.17 million shares or 13.38% of their US portfolio. Moreover, Gvo Asset Management Ltd has 10.83% invested in the company for 1.95 million shares. The New York-based Two Creeks Capital Management Lp has invested 10.56% in the stock. Crescent Park Management L.P., a California-based fund reported 748,664 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 1 buy, and 4 selling transactions for $3.24 million net activity.

Zoetis Inc (NYSE:ZTS) Ratings Coverage

Ratings analysis reveals 73% of Zoetis Inc’s analysts are positive. Out of 11 Wall Street analysts rating Zoetis Inc, 8 give it “Buy”, 1 “Sell” rating, while 2 recommend “Hold”. The lowest target is $48 while the high is $58. The stock’s average target of $53.50 is 6.68% above today’s ($50.15) share price. ZTS was included in 20 notes of analysts from July 24, 2015. The company was downgraded on Monday, September 7 by Zacks. The firm has “Buy” rating given on Thursday, September 17 by Zacks. The firm earned “Outperform” rating on Thursday, February 4 by Credit Suisse. The stock of Zoetis Inc (NYSE:ZTS) earned “Neutral” rating by Citigroup on Thursday, August 4. On Tuesday, March 15 the stock rating was maintained by Jefferies with “Buy”. The firm has “Outperform” rating given on Thursday, August 6 by William Blair. BMO Capital Markets upgraded the stock to “Outperform” rating in Friday, September 11 report. The stock has “Equal-Weight” rating given by Barclays Capital on Thursday, August 4. The rating was maintained by Jefferies with “Buy” on Tuesday, June 14. The firm earned “Sell” rating on Friday, May 6 by Goldman Sachs.

ZTS Company Profile

Zoetis Inc., incorporated on July 25, 2012, is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Firm has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Firm operates through two divisions: the United States and International. Within each of these divisions, the Company offers a diversified product portfolio for both livestock and companion animal customers. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ellis Scott

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>